Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Refractory/Relapsed Diffuse Large B-cell Lymphoma Patients with Failure of CAR-T Therapy

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Refractory/Relapsed Diffuse Large B-cell Lymphoma Patients with Failure of CAR-T Therapy

2024.04.10
In the challenging field of hematology, the search for effective treatments for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) after CAR-T therapy failure is crucial. Professor Professor Haiwen Huang from The First Affiliated Hospital of Soochow University leads an innovative study exploring allogeneic hematopoietic stem cell transplantation (allo-HSCT) as a promising alternative. This collaborative research not only offers new hope for R/R DLBCL patients but also showcases the pioneering spirit driving advancements in oncology. By providing valuable insights into allo-HSCT's potential, Professor Huang and his team contribute significantly to the evolving landscape of cancer treatment, highlighting the importance of innovation and teamwork in improving patient care.
Revolutionizing Multiple Myeloma Treatment: FCRL5-Directed CAR-T Cells Enhanced with IL-15 Show Promising Antitumor Activity

Revolutionizing Multiple Myeloma Treatment: FCRL5-Directed CAR-T Cells Enhanced with IL-15 Show Promising Antitumor Activity

2024.03.08
In January 2024, a study led by Professor Ting Niu from West China Hospital, Sichuan University was published in the international academic journal ——Signal Transduction And Targeted Therapy (IF=38.104). The title of the study is "Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma". This study sheds light on the promising potential of FCRL5-directed CAR-T cell therapy in the treatment of multiple myeloma (MM).
ESMO Expert Commentary | Roxadustat Non-inferior to Standard Treatment, Poised to Transform Clinical Practice in Chemotherapy-Induced Anemia

ESMO Expert Commentary | Roxadustat Non-inferior to Standard Treatment, Poised to Transform Clinical Practice in Chemotherapy-Induced Anemia

2024.01.22
Platinum-based, taxane, anthracycline, and other chemotherapy drugs are commonly used in the treatment of various cancers such as breast and lung cancer. However, these chemotherapy agents, known marrow suppressors, can lead to chemotherapy-induced anemia (CIA), resulting in a decline in functional capacity and diminished quality of life for patients. This year's ESMO conference revealed the results of a Phase III clinical study on roxadustat in treating CIA in patients with non-myeloid malignancies, offering a more convenient treatment option for CIA patients. "Oncology Frontier" is honored to invite Professor Yongmei Yin from Jiangsu Provincial People's Hospital and Professor Jian Zhang from Fudan University Cancer Hospital to share insights into the current challenges in CIA treatment and the significance of this study for CIA patients.
Dr.  Hui Wang: Unlocking a New Approach to MRD Testing in Acute Myeloid Leukemia

Dr.  Hui Wang: Unlocking a New Approach to MRD Testing in Acute Myeloid Leukemia

2024.01.15
The 49th European Bone Marrow Transplantation Annual Meeting (EBMT 2023) took place in Paris, France, from April 23 to 26, 2023. Experts and scholars from various countries gathered to present exciting advancements in research. In the field of blood tests, the fifty-year anniversary of flow cytometry coincided with this year's conference. Over the past half-century, this technology has become an indispensable tool in the diagnosis and follow-up of hematological malignancies. Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults, and the detection of Minimal Residual Disease (MRD) plays a crucial role in clinical treatment and prognosis assessment, despite encountering various technical challenges. With the release of two significant expert consensus statements by the European Leukemia Network (ELN) in 2018 and 2021, technical issues related to AML MRD detection by Multiparameter Flow Cytometry (MFC) were discussed, making this research once again the focus of the hematology field.
Revolutionizing Cancer Care: Dr. Tony Ng’s Pioneering Insights at the CCHIO Congress

Revolutionizing Cancer Care: Dr. Tony Ng’s Pioneering Insights at the CCHIO Congress

2023.11.30
Dr. Tony Ng, a renowned figure in the field of cancer research, recently participated in the 10-Day HIV-Related Congress. This event was a gathering of top minds in medicine, featuring doctors, scientists, and researchers from over 30 districts in China. Dr. Ng's role as a speaker at this congress highlighted his significant contributions to cancer research and management.